4.6 Article

The SUMO-specific protease SENP1 deSUMOylates p53 and regulates its activity

Journal

JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 122, Issue 2, Pages 189-197

Publisher

WILEY
DOI: 10.1002/jcb.29838

Keywords

p53; SENP1; SUMO; SUMO protease; SUMOylation

Funding

  1. National Institute of General Medical Sciences [R01 GM130604]
  2. National Cancer Institute [R01 CA160474, R01 CA186241]

Ask authors/readers for more resources

The study reveals that SENP1 is a critical p53 deSUMOylating enzyme, and its depletion induces p53 transactivation activity and synergizes with DNA damage-inducing agent etoposide to activate p53 and inhibit cancer cell growth.
The stability and activity of the p53 tumor suppressor protein are tightly regulated by various posttranslational modifications, including SUMOylation. p53 can be modified by both SUMO1 and SUMO2, although how SUMOylation regulates p53 activity is still obscure. Whether p53 activity is directly regulated by deSUMOylation is also unclear. Here, we show that SENP1, a SUMO-specific protease implicated in pro-oncogenic roles, is a p53 deSUMOylating enzyme. SENP1 interacts with p53 and deSUMOylates p53 in cells and in vitro. Knockdown of SENP1 markedly induced p53 transactivation activity. We further show that SENP1 depletion synergizes with DNA damage-inducing agent etoposide to induce p53 activation and the expression of p21, leading to synergistic growth inhibition of cancer cells. Our results reveal that SENP1 is a critical p53 deSUMOylating enzyme and a promising therapeutic target in wild-type p53 containing cancer cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available